ARANESP 40 MCG
DARBEPOETIN ALFA : 40 MCG · DIN 02392321 · AMGEN CANADA INC
Health Canada status: MARKETED
What is ARANESP?
ARANESP 40 MCG contains DARBEPOETIN ALFA : 40 MCG. It is listed in the Health Canada Drug Product Database under DIN 02392321, held by AMGEN CANADA INC, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 12-Mar-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02392321 |
|---|---|
| Brand name | ARANESP |
| Generic / active ingredient | DARBEPOETIN ALFA : 40 MCG |
| Manufacturer | AMGEN CANADA INC |
| Strength | 40 MCG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | B03XA02 DARBEPOETIN ALFA |
| AHFS class | 20:16.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Mar-2014 |
| Original market date | 2014-03-12 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B03XA02 DARBEPOETIN ALFA. 13 of 24 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ARANESP | 100 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02391759 |
| ARANESP | 100 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02391740 |
| ARANESP | 200 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02392356 |
| ARANESP | 200 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02391775 |
| ARANESP | 200 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02391783 |
| ARANESP | 200 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02391767 |
| ARANESP | 25 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02392313 |
| ARANESP | 300MCG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02391821 |
| ARANESP | 30MCG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02392348 |
| ARANESP | 500 MCG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02391805 |
Who else supplies DARBEPOETIN ALFA worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DARBEPOETIN ALFA appears in 162 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.